Gregory Glover | Blog
May 8, 2023
On August 13, 2021, FDA announced it would accept comments on a proposal to treat pre-Hatch-Waxman abbreviated new drug applications, or PANDAs, as NDAs. Despite objections, the agency is apparently already implementing changes.
With the 1984 Hatch-Waxman Amendments,... More